149 related articles for article (PubMed ID: 32524859)
1. How effective are nonalcoholic fatty liver disease models for drug discovery?
Hundertmark J; Tacke F
Expert Opin Drug Discov; 2020 Nov; 15(11):1237-1240. PubMed ID: 32524859
[TBL] [Abstract][Full Text] [Related]
2. Emerging Therapies and Therapeutic Targets for Composite Liver Disease: NASH.
Sobhia ME; Kumari S; Kumar H; Gandhe A; Kaushik D; Kumar H; Jain J; Ankita ; Mallick M; Pavani B; Moudgil M; Patel D
Curr Top Med Chem; 2023; 23(21):2027-2047. PubMed ID: 37455455
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis.
Iwaki M; Yoneda M; Wada N; Otani T; Kobayashi T; Nogami A; Saito S; Nakajima A
Expert Opin Emerg Drugs; 2024 Jun; 29(2):127-137. PubMed ID: 38469871
[TBL] [Abstract][Full Text] [Related]
4. Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis.
Oseini AM; Cole BK; Issa D; Feaver RE; Sanyal AJ
Hepatol Int; 2018 Jan; 12(1):6-16. PubMed ID: 29299759
[TBL] [Abstract][Full Text] [Related]
5. Zebrafish facilitate non-alcoholic fatty liver disease research: Tools, models and applications.
Chang C; Li H; Zhang R
Liver Int; 2023 Jul; 43(7):1385-1398. PubMed ID: 37122203
[TBL] [Abstract][Full Text] [Related]
6. Research and Progress of Probucol in Nonalcoholic Fatty Liver Disease.
Chen KQ; Ke BY; Cheng L; Guan MT; Wang ZB; Wang SZ
Mini Rev Med Chem; 2023; 23(19):1905-1911. PubMed ID: 36967462
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review.
Sandoval C; Reyes C; Rosas P; Godoy K; Souza-Mello V; Farías J
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958712
[TBL] [Abstract][Full Text] [Related]
8. Is MASLD lost in translation in mice?
Gunes A; Estall JL
Trends Endocrinol Metab; 2024 Jun; 35(6):459-461. PubMed ID: 38599902
[TBL] [Abstract][Full Text] [Related]
9. NAFLDkb: A Knowledge Base and Platform for Drug Development against Nonalcoholic Fatty Liver Disease.
Xu T; Gao W; Zhu L; Chen W; Niu C; Yin W; Ma L; Zhu X; Ling Y; Gao S; Liu L; Jiao N; Chen W; Zhang G; Zhu R; Wu D
J Chem Inf Model; 2024 Apr; 64(7):2817-2828. PubMed ID: 37167092
[TBL] [Abstract][Full Text] [Related]
10. Editorial: Resmetirom - a promising treatment option for NASH and liver fibrosis.
Targher G
Aliment Pharmacol Ther; 2024 Jan; 59(1):128-129. PubMed ID: 38085941
[No Abstract] [Full Text] [Related]
11. Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis.
Futatsugi K; Cabral S; Kung DW; Huard K; Lee E; Boehm M; Bauman J; Clark RW; Coffey SB; Crowley C; Dechert-Schmitt AM; Dowling MS; Dullea R; Gosset JR; Kalgutkar AS; Kou K; Li Q; Lian Y; Loria PM; Londregan AT; Niosi M; Orozco C; Pettersen JC; Pfefferkorn JA; Polivkova J; Ross TT; Sharma R; Stock IA; Tesz G; Wisniewska H; Goodwin B; Price DA
J Med Chem; 2022 Nov; 65(22):15000-15013. PubMed ID: 36322383
[TBL] [Abstract][Full Text] [Related]
12. In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations.
Lee YS; Seki E
Cell Mol Gastroenterol Hepatol; 2023; 16(3):355-367. PubMed ID: 37270060
[TBL] [Abstract][Full Text] [Related]
13. Editorial: Nitro-fatty acids: novel drug candidates for the co-treatment of atherosclerosis and nonalcoholic fatty liver disease.
Rom O; Liu Y; Chang L; Chen YE; Aviram M
Curr Opin Lipidol; 2020 Apr; 31(2):104-107. PubMed ID: 32132415
[No Abstract] [Full Text] [Related]
14. [Current status and challenges of clinical research and development of new drugs for liver diseases].
Shen ZY; Cai XB; Lu LG
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):289-294. PubMed ID: 38733180
[TBL] [Abstract][Full Text] [Related]
15. [Challenges and optimization strategies for clinical research and the development of new drugs for liver fibrosis].
Cai XB; Qu Y; Lu LG
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):303-305. PubMed ID: 38733183
[TBL] [Abstract][Full Text] [Related]
16. Disseminative Recurrence Signature for Hepatocellular Carcinoma From Nonalcoholic Fatty Liver Disease.
Fujiwara N; Kubota N; Zhu S; Nakagawa S; Baba H; Hoshida Y
Gastro Hep Adv; 2023; 2(5):681-683. PubMed ID: 37621719
[No Abstract] [Full Text] [Related]
17. Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research.
Flessa CM; Nasiri-Ansari N; Kyrou I; Leca BM; Lianou M; Chatzigeorgiou A; Kaltsas G; Kassi E; Randeva HS
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555433
[TBL] [Abstract][Full Text] [Related]
18. Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies.
Fang T; Wang H; Pan X; Little PJ; Xu S; Weng J
Int J Biol Sci; 2022; 18(15):5681-5697. PubMed ID: 36263163
[TBL] [Abstract][Full Text] [Related]
19. Modulation of Dietary Choline Uptake in a Mouse Model of Acid Sphingomyelinase Deficiency.
Gaudioso Á; Moreno-Huguet P; Casas J; Schuchman EH; Ledesma MD
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298714
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
